These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18059224)

  • 1. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.
    Schmitt AM; Anlauf M; Rousson V; Schmid S; Kofler A; Riniker F; Bauersfeld J; Barghorn A; Probst-Hensch NM; Moch H; Heitz PU; Kloeppel G; Komminoth P; Perren A
    Am J Surg Pathol; 2007 Nov; 31(11):1677-82. PubMed ID: 18059224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.
    Zhang L; Smyrk TC; Oliveira AM; Lohse CM; Zhang S; Johnson MR; Lloyd RV
    Am J Surg Pathol; 2009 Oct; 33(10):1562-9. PubMed ID: 19574886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of CK19 and CD99 in pancreatic endocrine tumors.
    Ali A; Serra S; Asa SL; Chetty R
    Am J Surg Pathol; 2006 Dec; 30(12):1588-94. PubMed ID: 17122516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm.
    Zhang L; Lohse CM; Dao LN; Smyrk TC
    Hum Pathol; 2011 Mar; 42(3):324-31. PubMed ID: 21190722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Support for a postresection prognostic score for pancreatic endocrine tumors.
    Hurtuk MG; Godambe AS; Shoup M; Yong S; Aranha GV
    Am J Surg; 2011 Mar; 201(3):406-10; discussion 410. PubMed ID: 21367388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients.
    Jonkers YM; Claessen SM; Perren A; Schmitt AM; Hofland LJ; de Herder W; de Krijger RR; Verhofstad AA; Hermus AR; Kummer JA; Skogseid B; Volante M; Voogd AC; Ramaekers FC; Speel EJ
    Endocr Relat Cancer; 2007 Sep; 14(3):769-79. PubMed ID: 17914106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers.
    La Rosa S; Adsay V; Albarello L; Asioli S; Casnedi S; Franzi F; Marando A; Notohara K; Sessa F; Vanoli A; Zhang L; Capella C
    Am J Surg Pathol; 2012 Dec; 36(12):1782-95. PubMed ID: 23026929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours.
    La Rosa S; Rigoli E; Uccella S; Novario R; Capella C
    Histopathology; 2007 Apr; 50(5):597-606. PubMed ID: 17394496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors.
    La Rosa S; Klersy C; Uccella S; Dainese L; Albarello L; Sonzogni A; Doglioni C; Capella C; Solcia E
    Hum Pathol; 2009 Jan; 40(1):30-40. PubMed ID: 18715612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.
    Hochwald SN; Zee S; Conlon KC; Colleoni R; Louie O; Brennan MF; Klimstra DS
    J Clin Oncol; 2002 Jun; 20(11):2633-42. PubMed ID: 12039924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of survivin in pancreatic endocrine tumors.
    Ekeblad S; Lejonklou MH; Stålberg P; Skogseid B
    World J Surg; 2012 Jun; 36(6):1411-8. PubMed ID: 22089920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses.
    Sakai Y; Hong SM; An S; Kim JY; Corbeil D; Karbanová J; Otani K; Fujikura K; Song KB; Kim SC; Akita M; Nanno Y; Toyama H; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
    Hum Pathol; 2017 Mar; 61():148-157. PubMed ID: 27864124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors.
    Deshpande V; Fernandez-del Castillo C; Muzikansky A; Deshpande A; Zukerberg L; Warshaw AL; Lauwers GY
    Am J Surg Pathol; 2004 Sep; 28(9):1145-53. PubMed ID: 15316313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.
    Scarpa A; Mantovani W; Capelli P; Beghelli S; Boninsegna L; Bettini R; Panzuto F; Pederzoli P; delle Fave G; Falconi M
    Mod Pathol; 2010 Jun; 23(6):824-33. PubMed ID: 20305616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant-functioning neuroendocrine tumors of the pancreas: A survival analysis.
    Keutgen XM; Nilubol N; Kebebew E
    Surgery; 2016 May; 159(5):1382-9. PubMed ID: 26704781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.
    Strosberg JR; Cheema A; Weber J; Han G; Coppola D; Kvols LK
    J Clin Oncol; 2011 Aug; 29(22):3044-9. PubMed ID: 21709192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CK19 and CD99 immunoexpression profile in goblet cell (mucin-producing neuroendocrine tumors) and classical carcinoids of the vermiform appendix.
    Alsaad KO; Serra S; Perren A; Hsieh E; Chetty R
    Int J Surg Pathol; 2007 Jul; 15(3):252-7. PubMed ID: 17652531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors.
    Cherenfant J; Talamonti MS; Hall CR; Thurow TA; Gage MK; Stocker SJ; Lapin B; Wang E; Silverstein JC; Mangold K; Odeleye M; Kaul KL; Lamzabi I; Gattuso P; Winchester DJ; Marsh RW; Roggin KK; Bentrem DJ; Baker MS; Prinz RA
    Surgery; 2014 Dec; 156(6):1504-10; discussion 1510-1. PubMed ID: 25456943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.